Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 155 No. 3 (2025)

VEXAS syndrome: a Swiss national retrospective cohort study

Cite this as:
Swiss Med Wkly. 2025;155:3879
Published
14.03.2024

Summary

STUDY AIMS: VEXAS syndrome is a recently discovered monogenic auto-inflammatory disease caused by a somatic mutation in the UBA1 gene that manifests with rheumatologic and haematologic features. In this report, we present the first Swiss cohort, detailing its manifestations and treatment outcomes among Swiss patients.

METHODS: Data were retrospectively collected from nine hospitals across Switzerland, representing a broad geographic distribution. Treating physicians completed a standardised case report form for each patient. The principal investigator and the co-investigators collected and analysed all case report forms.

RESULTS: We identified 23 patients between July 2022 and 2023, of which 17 are described. All were male. They presented with skin manifestations (88%), general symptoms (82%), venous thromboembolism (59%), ocular manifestation (59%), lung infiltrates (59%) and articular manifestations (47%). Central nervous system and kidney manifestations were very rare, and heart and digestive manifestations were absent. Macrocytic anaemia was present in all patients throughout the disease progression but only in two-thirds of patients (12/17, 71%) at the time of diagnosis. Clinical response was reached in all cases treated with ruxolitinib (4/4, 100%), upadacitinib (1/1, 100%), azacytidine (5/5, 100%) and haematopoietic stem cell transplantation (2/2, 100%). All deaths were attributed to infections (5/5, 100%).

CONCLUSION: This study corroborates the clinical spectrum of VEXAS syndrome described in other cohorts. It suggests that VEXAS syndrome is not limited to patients with macrocytic anaemia. In this study, azacytidine has been used effectively among patients with myelodysplastic syndrome. In addition, Janus kinase (JAK) inhibitors, particularly ruxolitinib, have been successfully used even in those without myelodysplastic syndrome. We report two successful treatments by haematopoietic stem cell transplantation.

References

  1. Jachiet V, Ricard L, Hirsch P, Malard F, Pascal L, Beyne-Rauzy O, et al.; MINHEMON: French Network of dysimmune disorders associated with hemopathies. Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases. Clin Exp Med. 2023 Jul;23(3):803–13. doi: https://doi.org/10.1007/s10238-022-00866-5
  2. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med. 2020 Dec;383(27):2628–38. doi: https://doi.org/10.1056/NEJMoa2026834
  3. Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E, et al.; French VEXAS group; GFEV, GFM, CEREMAIA, MINHEMON. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol. 2022 Mar;186(3):564–74. doi: https://doi.org/10.1111/bjd.20805
  4. Boyadzhieva Z, Ruffer N, Kötter I, Krusche M. How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies. Rheumatology (Oxford). 2023 Nov;62(11):3518–25. 10.1093/rheumatology/kead240
  5. Sujobert P, Heiblig M, Jamilloux Y. VEXAS: where do we stand 2 years later? Curr Opin Hematol. 2023 Mar;30(2):64–9. doi: https://doi.org/10.1097/MOH.0000000000000750
  6. Diarra A, Duployez N, Fournier E, Preudhomme C, Coiteux V, Magro L, et al. Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Adv. 2022 Feb;6(3):998–1003. 10.1182/bloodadvances.2021004749
  7. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007 Oct;370(9596):1453–7. doi: https://doi.org/10.1016/S0140-6736(07)61602-X
  8. van der Made CI, Potjewijd J, Hoogstins A, Willems HP, Kwakernaak AJ, de Sevaux RG, et al. Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS. J Allergy Clin Immunol. 2022 Jan;149(1):432–439.e4. doi: https://doi.org/10.1016/j.jaci.2021.05.014
  9. Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y, et al. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population. JAMA. 2023 Jan;329(4):318–24. doi: https://doi.org/10.1001/jama.2022.24836
  10. Stubbins RJ, McGinnis E, Johal B, Chen LY, Wilson L, Cardona DO, et al. VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome). Haematologica. 2022 Apr;107(4):1011–3. doi: https://doi.org/10.3324/haematol.2021.280238
  11. Ferrada MA, Savic S, Cardona DO, Collins JC, Alessi H, Gutierrez-Rodrigues F, et al. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood. 2022 Sep;140(13):1496–506. doi: https://doi.org/10.1182/blood.2022016985
  12. Beecher MB, Tong JY, Halliday LA, Hissaria P, Selva D. Recurrent orbital inflammation associated with VEXAS syndrome. Orbit. 2022;0(0):1–4.
  13. Koster MJ, Samec MJ, Warrington KJ. VEXAS Syndrome-A Review of Pathophysiology, Presentation, and Prognosis. J Clin Rheumatol. 2023 Sep;29(6):298–306. doi: https://doi.org/10.1097/RHU.0000000000001905
  14. Vitale A, Caggiano V, Martin-Nares E, Frassi M, Dagna L, Hissaria P, et al. Orbital/ocular inflammatory involvement in VEXAS syndrome: data from the international AIDA network VEXAS registry. Semin Arthritis Rheum. 2024 Jun;66:152430. 10.1016/j.semarthrit.2024.152430
  15. Sota J, Vitale A, Fabiani C, Frediani B, Rigante D, Tosi GM, et al. The eye involvement in monogenic autoinflammatory diseases: literature review and update. Clin Exp Rheumatol. 2018 Jan-Feb;36 Suppl 110(1):44-53.
  16. Sfiniadaki E, Tsiara I, Theodossiadis P, Chatziralli I. Ocular Manifestations of Granulomatosis with Polyangiitis: A Review of the Literature. Ophthalmol Ther. 2019 Jun;8(2):227–34. doi: https://doi.org/10.1007/s40123-019-0176-8
  17. Khitri MY, Guedon AF, Georgin-Lavialle S, Terrier B, Saadoun D, Seguier J, et al.; French VEXAS group and MINHEMON. Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients. RMD Open. 2022 Jul;8(2):e002255. doi: https://doi.org/10.1136/rmdopen-2022-002255
  18. Ferrada MA, Sikora KA, Luo Y, Wells KV, Patel B, Groarke EM, et al. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. Arthritis Rheumatol. 2021 Oct;73(10):1886–95. doi: https://doi.org/10.1002/art.41743
  19. Borie R, Debray MP, Guedon AF, Mekinian A, Terriou L, Lacombe V, et al.; French VEXAS Group. Pleuropulmonary Manifestations of Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome. Chest. 2023 Mar;163(3):575–85. doi: https://doi.org/10.1016/j.chest.2022.10.011
  20. Tsuchida N, Kunishita Y, Uchiyama Y, Kirino Y, Enaka M, Yamaguchi Y, et al. Pathogenic UBA1 variants associated with VEXAS syndrome in Japanese patients with relapsing polychondritis. Ann Rheum Dis. 2021 Aug;80(8):1057–61. doi: https://doi.org/10.1136/annrheumdis-2021-220089
  21. Akdoğan Ö, Exilus S, Ward BK, McArthur JC, Della Santina CC, Carey JP. Sudden Sensorineural Hearing and Vestibular Loss in a Case of Relapsing Polychondritis. Ann Otol Rhinol Laryngol. 2021 Dec;130(12):1412–6. doi: https://doi.org/10.1177/00034894211005979
  22. Muratore F, Marvisi C, Castrignanò P, Nicoli D, Farnetti E, Bonanno O, et al. VEXAS syndrome: a case series from a single-center cohort of Italian patients with vasculitis. Arthritis Rheumatol. 2021; n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.41992
  23. Watanabe R, Kiji M, Hashimoto M. Vasculitis associated with VEXAS syndrome: A literature review. Front Med (Lausanne). 2022 Aug;9:983939. Available from: https://www.frontiersin.org/articles/10.3389/fmed.2022.983939 10.3389/fmed.2022.983939
  24. Obiorah IE, Patel BA, Groarke EM, Wang W, Trick M, Ombrello AK, et al. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv. 2021 Aug;5(16):3203–15. doi: https://doi.org/10.1182/bloodadvances.2021004976
  25. Gutierrez-Rodrigues F, Kusne Y, Fernandez J, Lasho T, Shalhoub R, Ma X, et al. Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood. 2023 Jul;142(3):244–59. doi: https://doi.org/10.1182/blood.2022018774
  26. Battipaglia G, Vincenzi A, Falconi G, Fiore A, D’Agostino F, Iannotta R, et al. New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: evolution from myelodysplastic syndrome to acute myeloid leukemia. Curr Res Transl Med. 2023;71(2):103386. doi: https://doi.org/10.1016/j.retram.2023.103386
  27. Terrier B, Posseme C, Temple M, Corneau A, Carbone F, Chenevier-Gobeaux C, et al. Le syndrome VEXAS se caractérise par une activation des voies de l’inflammasome dans le sang et les tissus et par une dérégulation du compartiment monocytaire. Rev Med Interne. 2022 Dec;43:A384. 10.1016/j.revmed.2022.10.097
  28. Staels F, Betrains A, Woei-A-Jin FJ, Boeckx N, Beckers M, Bervoets A, et al. Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome. Front Immunol. 2021 Apr;12:678927. doi: https://doi.org/10.3389/fimmu.2021.678927
  29. Yoon JG, Lee S, Kim S, Kim MJ, Chang YH, Park JK, et al. The First Korean Case of VEXAS Syndrome Caused by a UBA1 Somatic Variant. Ann Lab Med. 2023 Mar;43(2):217–20. doi: https://doi.org/10.3343/alm.2023.43.2.217
  30. Heiblig M, Ferrada MA, Gerfaud-Valentin M, Barba T, Mékinian A, Koster M, et al. Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective Study. Blood. 2021 Nov;138 Supplement 1:2608. doi: https://doi.org/10.1182/blood-2021-150394
  31. Heiblig M, Ferrada MA, Koster MJ, Barba T, Gerfaud-Valentin M, Mékinian A, et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood. 2022 Aug;140(8):927–31. doi: https://doi.org/10.1182/blood.2022016642
  32. Comont T, Heiblig M, Rivière E, Terriou L, Rossignol J, Bouscary D, et al.; French VEXAS study group, Groupe Francophone des Myélodysplasies (GFM) and MedecineINterne, HEmato et ONco (MINHEMON) group. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br J Haematol. 2022 Feb;196(4):969–74. doi: https://doi.org/10.1111/bjh.17893
  33. Bourbon E, Heiblig M, Gerfaud Valentin M, Barba T, Durel CA, Lega JC, et al. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood. 2021 Jul;137(26):3682–4. doi: https://doi.org/10.1182/blood.2020010177
  34. Campochiaro C, Tomelleri A, Cavalli G, De Luca G, Grassini G, Cangi MG, et al. Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series. Arthritis Rheumatol. 2022 Jul;74(7):1302–3. doi: https://doi.org/10.1002/art.42101